Class 3 Medicines Recall: Bristol-Myers Squibb Pharmaceuticals Limited, OPDIVO 10 mg/mL concentrate for solution for infusion (nivolumab), EL(24)A/11
Bristol-Myers Squibb Pharmaceuticals Limited has informed the MHRA that a potential product quality issue has been detected, relating to incomplete crimping of the metal crimp cap of OPDIVO 10mg/mL concentrate for solution for infusion (nivolumab) (1VLX10ML).
MDR Number: MDR 181-03/24
Company name: Bristol-Myers Squibb Pharmaceuticals Limited
Product description: OPDIVO 10 mg/mL concentrate for solution for infusion (nivolumab), PLGB 15105/0133
SNOMED Code: 29887611000001103
Details of the affected batch:
| Batch Number | Expiry Date | Pack Size | First Distributed |
| 8053520 | 31/12/2025 | 1 | 10/11/2023 |
Active Pharmaceutical Ingredient: nivolumab
Brief description of problem:
Bristol-Myers Squibb Pharmaceuticals Limited has informed the MHRA that a potential product quality issue has been detected, relating to incomplete crimping of the metal crimp cap of OPDIVO 10mg/mL concentrate for solution for infusion (nivolumab) (1VLX10ML). Four thousand (4,000) units of the concerned batch, specified in the above table, was distributed in Great Britain (GB) between 10 November 2023 - 5 December 2023. This defect has been reported in vials manufactured from the same bulk batch in another market, although no defects have been reported in the UK market.
Advice to Healthcare Professionals:
Stop using the above batches immediately. Quarantine all remaining stock and return it to your supplier using your supplier’s approved process. No further action is required concerning product that has already been administered.
Advice to Patients:
No action is required by patients as this is a Pharmacy and Wholesaler level recall. This product is administered by healthcare professionals directly. If you have concerns about a medicine you may be using, please contact your healthcare professional.
Patients who experience adverse reactions or have any questions about the medication should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme
Company contacts for further information:
For medical information enquiries please contact the Bristol Myers Squibb Medical Information Department by phone (0800 731 1736) or email medical.information@bms.com.
To access the full recall: